ATE304709T1 - Substanzen mit verzweigten linkermolekülen - Google Patents

Substanzen mit verzweigten linkermolekülen

Info

Publication number
ATE304709T1
ATE304709T1 AT01985752T AT01985752T ATE304709T1 AT E304709 T1 ATE304709 T1 AT E304709T1 AT 01985752 T AT01985752 T AT 01985752T AT 01985752 T AT01985752 T AT 01985752T AT E304709 T1 ATE304709 T1 AT E304709T1
Authority
AT
Austria
Prior art keywords
substances
linker molecules
branched linker
branched linkers
branched
Prior art date
Application number
AT01985752T
Other languages
English (en)
Inventor
Herbert Andres
Hans-Peter Josel
Eva Hoess
Rupert Herrmann
Der Eltz Herbert Von
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE304709T1 publication Critical patent/ATE304709T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01985752T 2000-09-29 2001-09-26 Substanzen mit verzweigten linkermolekülen ATE304709T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10048417A DE10048417A1 (de) 2000-09-29 2000-09-29 Verbindungen mit verzweigtem Linker
PCT/EP2001/011118 WO2002027315A2 (en) 2000-09-29 2001-09-26 Compounds with a branched linker

Publications (1)

Publication Number Publication Date
ATE304709T1 true ATE304709T1 (de) 2005-09-15

Family

ID=7658168

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01985752T ATE304709T1 (de) 2000-09-29 2001-09-26 Substanzen mit verzweigten linkermolekülen

Country Status (10)

Country Link
US (2) US20040086943A1 (de)
EP (1) EP1327146B1 (de)
JP (1) JP3647845B2 (de)
AT (1) ATE304709T1 (de)
AU (1) AU2002215904A1 (de)
CA (1) CA2423916C (de)
DE (2) DE10048417A1 (de)
DK (1) DK1327146T3 (de)
ES (1) ES2248405T3 (de)
WO (1) WO2002027315A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
JP2003535208A (ja) 2000-06-08 2003-11-25 ラ ホヤ ファーマシューティカル カンパニー 高分子量ポリエチレン・オキシドを含む多価プラットホーム分子
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP1392359B2 (de) 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Spezifische bindungsproteine und ihre verwendung
US20030199466A1 (en) 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
DE10227599B4 (de) * 2002-06-20 2005-04-28 Proteome Factory Ag Verfahren und Reagenz zur spezifischen Identifizierung und Quantifizierung von einem oder mehreren Proteinen in einer Probe
DE10393455D2 (de) * 2002-07-19 2005-06-16 Mologen Ag DNA-Expressionskonstrukt zur multiplen Genexpression
GB0329825D0 (en) 2003-12-23 2004-01-28 Celltech R&D Ltd Biological products
WO2006011543A1 (ja) * 2004-07-30 2006-02-02 Advanced Life Science Institute, Inc. プローブ複合体
WO2007059760A1 (de) 2005-11-25 2007-05-31 Mologen Ag Dna-konstrukte zur spezifischen hemmung der genexpression durch rna-interferenz
GB0607479D0 (en) * 2006-04-13 2006-05-24 Johnson Matthey Plc Adhesion promoting compound
US9090693B2 (en) 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
CN101688229B (zh) 2007-03-15 2013-06-12 路德维格癌症研究所 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途
ES2609915T3 (es) 2007-08-14 2017-04-25 Ludwig Institute For Cancer Research Ltd. Anticuerpo monoclonal 175 direccionado al receptor de EGF y derivados y usos del mismo
US20110177619A1 (en) * 2008-07-14 2011-07-21 Andrew Metters In vitro diagnostic markers comprising carbon nanoparticles and kits
CN103588801A (zh) * 2013-12-02 2014-02-19 天津大港油田圣达科技有限公司 一种微量元素井间示踪剂的使用方法
CA3122316A1 (en) * 2018-12-21 2020-06-25 Seagen Inc. Adcs with thiol multiplex linkers
CN118362716A (zh) 2018-12-28 2024-07-19 雅培制药有限公司 微粒上的单分子的直接检测
JP7646667B2 (ja) * 2019-12-18 2025-03-17 スタンダード バイオツールズ カナダ インコーポレイテッド シグナル増幅のためのマスサイトメトリー試薬および方法
CN119775256B (zh) * 2024-12-31 2025-09-19 英科新创（苏州）生物科技有限公司 吖啶磺酰胺衍生物、制备方法、其应用及试剂盒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK365785A (da) * 1984-09-17 1986-03-18 Hoffmann La Roche Metalcomplexer
US5075447A (en) * 1984-09-17 1991-12-24 Hoffmann-La Roche Inc. Ruthenium complexes useful as carriers for immunologically active materials
FR2579224B1 (fr) * 1985-03-25 1987-05-22 Genetica Procede de preparation microbiologique de la serum-albumine humaine
US5750409A (en) * 1991-11-18 1998-05-12 Boehringer Mannheim Gmbh Pentacyclic compounds and their use as absorption or fluorescent dyes
GB9215780D0 (en) * 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
DE4310141A1 (de) * 1993-03-29 1994-10-06 Boehringer Mannheim Gmbh Homobidentale trifunktionelle Linker
GB9407812D0 (en) * 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
DE59508391D1 (de) * 1994-07-25 2000-06-29 Roche Diagnostics Gmbh Metallkomplexe mit geladenem linker
AU689626B2 (en) * 1994-07-25 1998-04-02 Boehringer Mannheim Gmbh Peptides marked with metal chelates
CN1148578C (zh) * 1994-07-25 2004-05-05 罗切诊断学有限公司 免疫测定特异抗体的方法、所用试剂、抗原及其用途
ES2171190T3 (es) * 1994-07-25 2002-09-01 Roche Diagnostics Gmbh Peptidos marcados con haptenos.
WO1996003410A1 (de) * 1994-07-25 1996-02-08 Boehringer Mannheim Gmbh Hydrophile metallkomplexe
US5718915A (en) * 1994-10-31 1998-02-17 Burstein Laboratories, Inc. Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme
DE19519973A1 (de) * 1995-05-31 1996-12-05 Boehringer Mannheim Gmbh Entstörungsreagenz für die Bestimmung eines Analyten mit einem lumineszenzfähigen Metallkomplex
US5714360A (en) * 1995-11-03 1998-02-03 Bsi Corporation Photoactivatable water soluble cross-linking agents containing an onium group
AU5159798A (en) * 1996-11-05 1998-05-29 Bristol-Myers Squibb Company Branched peptide linkers
US6362254B2 (en) * 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
DE19811582A1 (de) * 1998-03-17 1999-09-23 Roche Diagnostics Gmbh Stabilisierung und Verstärkung von Elektrochemilumineszenz-Signalen
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
EP1117540B1 (de) * 1998-09-29 2004-03-03 Hewlett-Packard Company, A Delaware Corporation Verfahren und vorrichtung zur herstellung von broschüren
GB2413081A (en) * 2004-04-13 2005-10-19 Sca Hygiene Prod Ab Absorbant article with folded side flap portions and method of manufacture

Also Published As

Publication number Publication date
JP3647845B2 (ja) 2005-05-18
EP1327146B1 (de) 2005-09-14
CA2423916C (en) 2009-02-03
CA2423916A1 (en) 2002-04-04
DE60113445T2 (de) 2006-06-29
EP1327146A2 (de) 2003-07-16
US20090264618A1 (en) 2009-10-22
ES2248405T3 (es) 2006-03-16
JP2004510160A (ja) 2004-04-02
DE10048417A1 (de) 2002-04-11
WO2002027315A3 (en) 2002-07-11
US20040086943A1 (en) 2004-05-06
AU2002215904A1 (en) 2002-04-08
DE60113445D1 (de) 2005-10-20
WO2002027315A2 (en) 2002-04-04
DK1327146T3 (da) 2006-01-23

Similar Documents

Publication Publication Date Title
ATE304709T1 (de) Substanzen mit verzweigten linkermolekülen
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
EP2357006A3 (de) Arzneimittelkonjugate und deren Verwendung zur Behandlung von Krebs, einer Autoimmunerkrankung oder einer Infektionskrankheit
EA200800657A1 (ru) Способ приготовления очищенных конъюгатов лекарственных средств
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
PT1144459E (pt) Acidos hialuronicos reticulados e as suas utilizacoes em medicina
MA26886A1 (fr) Acides malonamiques et leurs derives, utiles comme ligands de recepteurs thyroidiens.
TW200505942A (en) Antibody molecules having specificity for human IL-1β
CY1114922T1 (el) Κυτταροτοξικοι παραγοντες οι οποιοι περιλαμβανουν νεα παραγωγα τομαϋμυκινης και τη θεραπευτικη τους χρηση
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
DE60042369D1 (de) Chemisch programmierbare immunität
ATE296105T1 (de) Iminbildende polysaccharide, deren herstellung und verwendung als zusatzmittel und immunstimulierende mittel
AU1922902A (en) Novel means for the diagnosis and therapy of CTCL
WO2004013307A3 (en) Compounds for targeting hepatocytes
WO2006002895A3 (en) Conjugates of antibody and duoarmycin derivatives as antitumor agents
SE0003476D0 (sv) Compounds
ATE280588T1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
DE69840673D1 (de) Modifizierte polysaccharide mit veränderter biologischer erkennung
ATE507844T1 (de) Verfahren zur herstellung eines homogenen doxorubicin-transferrin kojugates
AU2002360350A1 (en) Peptides that home to tumor lymphatic vasculature and methods of using same
ATE321768T1 (de) Linker-nucleosid, seine herstellung und verwendung
UY26170A1 (es) Antigeno (c42) asociados a tumores
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
TR200103405T2 (tr) İkiişlevli antikorlar ve bunların tümör-önleyici amilleri hedeflemede kullanımı.
AR023794A1 (es) Antigeno asociado con tumores

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1327146

Country of ref document: EP